Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenshen Yizhi Fang, also known as Bushen-Yizhi formula (BSYZ), is a Traditional Chinese Medicine (TCM) prescription composed of multiple herbal ingredients. It has been investigated as a therapeutic agent for Alzheimer's disease (AD). Its proposed mechanisms of action involve regulating amyloid-β metabolism and suppressing neuronal apoptosis. Through a systems pharmacology approach, it has been shown to target various proteins, including calcium-dependent kinases, apoptosis/anti-apoptosis kinases, metalloelastases, glutamate receptors, nerve growth factor receptors, and Cathepsin D. Research has demonstrated its therapeutic effects on cognitive dysfunction in animal models of AD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenshen Yizhi Fang.